MCL-1 as a tumor microenvironment-linked survival node in cholangiocarcinoma

Cholangiocarcinoma remains a highly lethal malignancy characterized by marked biological heterogeneity, extensive desmoplasia, and limited long-term benefit from systemic therapy. Although recent therapeutic advances have modestly improved outcomes, prognosis remains poor, highlighting the need to define survival mechanisms that connect tumor-cell fitness with the tumor microenvironment. In this Perspective, we argue that myeloid cell leukemia-1 (MCL-1) should be regarded not simply as an anti-apoptotic BCL-2 family protein, but as a tumor microenvironment-linked survival node in cholangiocarcinoma. Experimental studies have shown that MCL-1 mediates resistance to TRAIL-induced apoptosis, is reinforced by inflammatory IL-6 signaling, and is upregulated by leukemia inhibitory factor through a PI3K/AKT-dependent pathway that protects tumor cells from chemotherapy-induced apoptosis. In parallel, stromal remodeling studies and FGFR-related mitochondrial MCL-1 biology suggest that MCL-1 sits at the interface of desmoplasia, cytokine-driven survival signaling, and mitochondrial fitness. In a commercially available cholangiocarcinoma tissue microarray, MCL-1 positivity was observed in 40 of 54 primary cholangiocarcinomas (74.1%). In unadjusted analysis, MCL-1 expression showed an exploratory association with tumor status (pT, Fisher's exact P = 0.043), whereas no clear association was observed with sex, age, or nodal status. These findings support the practical plausibility of MCL-1 as a tissue-level indicator of survival-favored cholangiocarcinoma biology. Framing MCL-1 in this way may help reposition therapy toward disruption of tumor-promoting microenvironmental circuitry rather than tumor-cell killing alone.